Celyad Competitors and Similar CompaniesClear all
Alnylam's competitors and similar companies include Sorrento Therapeutics.
 Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
| |
Founding Date | Founding Date 2002 | Founding Date 2006 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations San Diego, US HQ San Diego, US | |
Employees | Employees 1,32324% increase | Employees 31019% decrease |
Valuation ($) | Valuation ($) 36.5 b | Valuation ($) 1.5 m |
Financial | ||
Revenue (est.) | Revenue (est.) $3.7b (FY, 2025) | Revenue (est.) $62.8m (FY, 2022) |
Net income | Net income $313.7m (FY, 2025) | Net income ($577.8m) (FY, 2022) |
Funding | ||
Total funding raised | Total funding raised $ 1.5b | Total funding raised $ 42.6m |
For sources of this data, please see the company profile
View Company Profiles
Sorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View company